Study to Evaluate the effIcacy and Safety of Abelacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral Anticoagulation
A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 2500 participants.
Also called NCT07739888
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 2,500 participants
- Sponsor
- Registry
-
NCT07739888
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Not reported
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07739888. Allocation not applicable; no masking; primary purpose treatment. Start 2027-12-30 (anticipated); primary completion 2030-12-30 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study to Evaluate the effIcacy and Safety of Abelacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral Anticoagulation
- Acronym
- LILAC-TIMI 76
- Condition
- Atrial Fibrillation (AF)
- Intervention (Biological)
- Abelacimab
- Lead sponsor
- Novartis Pharmaceuticals
Record details
- Record id
cardio:ct-nct07739888- Content hash
db5cd7d06176f39e3f01b2b73fa5cd6eec1e771f3cc9e69c0c0ad7d9f0b259e0